prikaz prve stranice dokumenta Učinak siRNA TMPRSS2-ERG u kombinaciji s antiandrogenima pri liječenju raka prostate
Access restricted to students and staff of home institution
master's thesis
Učinak siRNA TMPRSS2-ERG u kombinaciji s antiandrogenima pri liječenju raka prostate
Zagreb: University of Zagreb, Faculty of Food Technology and Biotechnology, 2015. urn:nbn:hr:159:083555
Slamić, Mateja
University of Zagreb
Faculty of Food Technology and Biotechnology
Department of Biochemical Engineering
Laboratory for Biology and Microbial Genetics

Institutional repository: Repository of the Faculty of Food Technology and Biotechnology

Cite this document

Slamić, M. (2015). Učinak siRNA TMPRSS2-ERG u kombinaciji s antiandrogenima pri liječenju raka prostate (Master's thesis). Zagreb: University of Zagreb, Faculty of Food Technology and Biotechnology. Retrieved from https://urn.nsk.hr/urn:nbn:hr:159:083555

Slamić, Mateja. "Učinak siRNA TMPRSS2-ERG u kombinaciji s antiandrogenima pri liječenju raka prostate." Master's thesis, University of Zagreb, Faculty of Food Technology and Biotechnology, 2015. https://urn.nsk.hr/urn:nbn:hr:159:083555

Slamić, Mateja. "Učinak siRNA TMPRSS2-ERG u kombinaciji s antiandrogenima pri liječenju raka prostate." Master's thesis, University of Zagreb, Faculty of Food Technology and Biotechnology, 2015. https://urn.nsk.hr/urn:nbn:hr:159:083555

Slamić, M. (2015). 'Učinak siRNA TMPRSS2-ERG u kombinaciji s antiandrogenima pri liječenju raka prostate', Master's thesis, University of Zagreb, Faculty of Food Technology and Biotechnology, accessed 22 November 2024, https://urn.nsk.hr/urn:nbn:hr:159:083555

Slamić M. Učinak siRNA TMPRSS2-ERG u kombinaciji s antiandrogenima pri liječenju raka prostate [Master's thesis]. Zagreb: University of Zagreb, Faculty of Food Technology and Biotechnology; 2015 [cited 2024 November 22] Available at: https://urn.nsk.hr/urn:nbn:hr:159:083555

M. Slamić, "Učinak siRNA TMPRSS2-ERG u kombinaciji s antiandrogenima pri liječenju raka prostate", Master's thesis, University of Zagreb, Faculty of Food Technology and Biotechnology, Zagreb, 2015. Available at: https://urn.nsk.hr/urn:nbn:hr:159:083555

Metadata
TitleUčinak siRNA TMPRSS2-ERG u kombinaciji s antiandrogenima pri liječenju raka prostate
Title (english)Effects of siRNA TMPRSS2-ERG combined with antiandrogens in prostate cancer
AuthorMateja Slamić
MentorAndreja Ambriović Ristov (mentor)
GranterUniversity of Zagreb
Faculty of Food Technology and Biotechnology
(Department of Biochemical Engineering)
(Laboratory for Biology and Microbial Genetics)
Zagreb
Defense date and country2015-02-26, Croatia
Scientific / art field,
discipline and subdiscipline		BIOTECHNICAL SCIENCES
Biotechnology
Abstract
Cilj ovog rada je bio pronaći prikladnu terapiju za rak prostate kombinacijom dva različita pristupa, hormonalne i genske terapije. Monoterapija antiandrogenima se koristi pri liječenju raka prostate, a mehanizam se zasniva na blokiranju androgen receptora. Genska terapija se u ovom slučaju bazira na činjenici da se u više od 50 % slučajeva raka prostate nalazi fuzija TMPRSS2-ERG. Dakle, cilj je bio kombinirati flutamid (nesteroidni antiandrogen) sa siRNA TMPRSS2-ERG kako bi se smanjila ekspresija TMPRSS2-ERG mRNA i ERG proteina in vitro, te rast tumora in vivo. U eksperimentalnom dijelu rada korišteni su VCaP stanična linija te SCID miševi. Rezultati pokazuju da kombinacija flutamida i siRNA TMPRSS2-ERG nije poboljšala djelovanje flutamida na ekspresiju TMPRSS2-ERG in vitro, kao ni rast tumora in vivo.
Abstract (english)
The aim of this thesis was to find appropriate treatment for prostate cancer by combination of two different approaches. The first one is based on the antiandrogen monotherapy which is used as conventional therapy of prostate cancer and the second one on the fact that prostate cancers carry oncofusion TMPRSS2-ERG in more than 50 % of cases. The idea was to combine flutamide (a nonsteroidal antiandrogen) with siRNA (designed against TMPRSS2-ERG fusion) in order to reduce TMPRSS2-ERG mRNA expression and ERG protein expression in vitro, and to reduce tumor growth in vivo. Studies are performed on VCaP cell line and SCID mice. Our results showed that the combination of flutamide and siRNA TMPRSS2-ERG did not enhance either in vitro, cell death and TMPRSS2-ERG inhibition or in vivo the tumor regression. This suggests that the siRNA TMPRSS2-ERG can be used as an alternative in androgen-independent phase.
Keywords
Keywords (english)
Languageenglish
URN:NBNurn:nbn:hr:159:083555
Study programmeTitle: Molecular Biotechnology
Study programme type: university
Study level: graduate
Academic / professional title: magistar/magistra inženjer/inženjerka molekularne biotehnologije (magistar/magistra inženjer/inženjerka molekularne biotehnologije)
Type of resourceText
File originBorn digital
Access conditionsAccess restricted to students and staff of home institution
Terms of useLicence In copyright icon
Created on2017-05-02 12:24:34